Efficacy and Safety of Optilume Drug-Coated Balloon for Urethral Stricture Treatment
Author Information
Author(s): Muacevic Alexander, Adler John R, Estaphanous Peter, Khalifa Ahmed O, Makar Youstina
Primary Institution: University Hospitals Coventry and Warwickshire
Hypothesis
Does the Optilume drug-coated balloon improve outcomes for patients with urethral strictures?
Conclusion
The Optilume drug-coated balloon is a promising treatment for urethral strictures, showing significant improvements in symptoms and low recurrence rates.
Supporting Evidence
- Optilume DCB showed a mean IPSS reduction of 13 points.
- QMax improved by an average of 10.11 mL/s after treatment.
- The recurrence-free rate was approximately 80.83%.
- The complication rate was low at 9.5%, with mostly mild adverse events.
- Optilume DCB is a minimally invasive alternative to standard treatments.
Takeaway
The Optilume balloon helps people with a narrow urethra feel better by opening it up and preventing it from getting narrow again.
Methodology
This systematic review and meta-analysis included seven studies assessing the efficacy and safety of Optilume DCB in treating urethral strictures.
Potential Biases
No significant evidence of publication bias was found.
Limitations
Some studies had short follow-up periods, and there were few randomized controlled trials.
Participant Demographics
The studies included a mix of male patients with urethral strictures, primarily affecting older adults.
Statistical Information
P-Value
<0.0001
Confidence Interval
95% CI: -15.8 to -10.3 for IPSS; 95% CI: +7.8 to +12.4 for QMax; 95% CI: 15.2% to 23.1% for recurrence rate
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website